1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher percentage of patients with a pathological complete...

1. Patients in the control group had higher mean health care utilization costs across the following measures: total unplanned expenditures,...

1. Carotuximab in tandem with pazopanib did not show improvement in progression-free survival or overall survival than pazopanib alone 2....

1. Overall survival was significantly longer in patients taking darolutamide in tandem with androgen-deprivation therapy and docetaxel. 2. Frequency of...

1. Treatment with pembrolizumab yielded a best overall response rate of 71%. 2. Adverse events occurred in 76% of patients,...

1. The incremental cost-effectiveness ratio of the pertuzumab group was $436,679 per QALY gained. 2. Even if pertuzumab were free,...

1. Disease control was reported in over half of the patients treated with abemaciclib 2. Most common adverse events included...

1. Olaparib led to a bigger decrease in pain interference and symptomatic skeletal-related events than hormonal drugs. 2. Olaparib demonstrated...

1. The use of a neoadjuvant gemcitabine-based chemoradiotherapy before surgery and adjuvant gemcitabine increased the overall survival rate when compared...

1. The median progression-free survival and overall survival was longer with lenvatinib plus pembrolizumab than with chemotherapy. 2. Clinically important...